


RESEARCH ARTICLE

Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology

Anita L. Sunde^{1,2}  | Ingvild V. Alsnes³ | Dag Aarsland^{1,4} | Nicholas J. Ashton^{1,5,6,7} |
Diego A. Tovar-Rios^{1,8,9} | Giovanni De Santis⁵ | Kaj Blennow⁵ |
Henrik Zetterberg^{5,10,11,12,13} | Svein R. Kjosavik¹⁴

¹Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway

²Department of Clinical Medicine, University of Bergen, Bergen, Norway

³Department of Public Health, University of Stavanger, Stavanger, Norway

⁴Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK

⁵Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

⁶King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute London, London, UK

⁷NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK

⁸Faculty of Health Sciences, University of Stavanger, Stavanger, Norway

⁹Grupo INFERIR, Facultad de Ingeniería, Universidad del Valle, Santiago de Cali, Valle del Cauca, Colombia

¹⁰Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

¹¹Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK

¹²UK Dementia Research Institute at UCL, London, UK

¹³Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China

¹⁴The General Practice and Care Coordination Research Group, Stavanger University Hospital, Stavanger, Norway

Correspondence

Anita L. Sunde, Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, P.O. box 8100, 4068 Stavanger, Norway.
Email: anita.lenora.sunde@sus.no

Funding information

Western Norway Regional Health Authority, Grant/Award Numbers: F-12583, 2021

Abstract

Introduction: Plasma tests have demonstrated high diagnostic accuracy for identifying Alzheimer's disease pathology. To facilitate the transition to clinical utility, we assessed whether plasma storage duration and temperature affect the biomarker concentrations.

Methods: Plasma samples from 13 participants were stored at +4°C and +18°C. Concentrations of six biomarkers were measured after 2, 4, 6, 8, 10, and 24 h by single molecule array assays.

Results: Phosphorylated tau 181 (p-tau181), phosphorylated tau 231 (p-tau231), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) concentrations were unchanged both when stored at +4°C and +18°C. Amyloid-β 40 (Aβ40) and amyloid-β 42 (Aβ42) concentrations were stable for 24 h at +4°C but declined when stored at +18°C for longer than 6 h. This decline did not affect the Aβ42/Aβ40 ratio.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

Discussion: Plasma samples can be stored for 24 h at +4°C or +18°C and result in valid assay results for p-tau181, p-tau231, A β 42/A β 40 ratio, GFAP, and NfL.

KEYWORDS

Alzheimer disease, amyloid beta, biomarker, glial fibrillary acidic protein, neurofilament protein light, phosphorylated tau, plasma, pre-analytics

HIGHLIGHTS

- Plasma samples were stored for 24 h at +4°C and +18°C, mimicking clinical practice.
- Concentrations for Alzheimer's disease biomarkers were measured at six time-points.
- p-tau181, p-tau231, NfL, and GFAP concentrations were unchanged during the experiment.
- Storage at +18°C affected A β 40 and A β 42 concentrations while storage at +4°C did not. The A β 42/A β 40 ratio was unaffected.
- These plasma tests seem suitable for use in general practice.

1 | BACKGROUND

Alzheimer's disease (AD) is the most common form of dementia. At present, an in vivo diagnosis can be made using molecular biomarkers in cerebrospinal fluid (CSF) and positron emission tomography (PET)¹; yet, a definitive diagnosis can still only be made post-mortem. CSF and PET diagnostic procedures are highly accurate for the underlying pathology of AD, but the high cost and minimal accessibility hamper their feasibility. The expected rise in dementia prevalence in the coming years² and the increasing need for evidence of underlying AD pathology before entering anti-amyloid therapeutic trials enhance the relevance of an early, more accessible, and cost-effective measure of AD.

Ultrasensitive blood tests predicting AD pathologies, amyloid- β , and tau, in the brain have shown potential for both diagnostic and prognostic clinical application.³⁻⁷ Among the most promising blood-based biomarkers are plasma phosphorylated tau 181 (p-tau181)^{8,9} and phosphorylated tau 231 (p-tau231).¹⁰ Other plasma biomarkers that might aid future diagnostics of AD are plasma glial fibrillary acidic protein (GFAP),¹¹ plasma amyloid- β 42 to amyloid- β 40 ratio (A β 42/A β 40 ratio),¹² and plasma neurofilament light (NfL).¹³ The combination of different biomarkers has also shown promising results.¹⁴

Due to the prospect that these plasma assays may greatly improve the diagnostic accuracy of AD pathology, a study of the possibility to use these tests in general practice is warranted. It has been shown that patients assessed for cognitive decline in primary healthcare had higher age, poorer cognition, and more limitations in activities of daily living than patients assessed in specialist healthcare.¹⁵ Reviews suggest that primary care providers experience difficulty recognizing early AD,¹⁶ lack confidence with diagnosing dementia, and express the need for better screening and diagnostic tools.¹⁷ However, there are certain demands a blood test administered in primary care must fulfill to be of

practical use. Primary care centers do not have the facilities to analyze high-technology assays and seldom have immediate access to ultra-low temperature freezers. Therefore, the plasma samples have to be stored and transported to a central laboratory for analysis. It is crucial to know if the storage temperature and duration of time from phlebotomy to ultra-low temperature freezing (ULTF) of the plasma affect the result of the assays.

This study aimed to assess the stability of ultrasensitive assays of plasma p-tau181, p-tau231, GFAP, A β 40, A β 42, and NfL for sample storage temperature and duration of time from phlebotomy to ULTF.

2 | METHODS

2.1 | Design

Blinded, controlled experiment.

2.2 | Sample

Four general practitioner (GP) offices in the Stavanger area, with at least three GPs per office, were selected for recruiting patients, based on their proximity to Stavanger University Hospital and willingness to help with recruitment. Additional participants were recruited from the Centre for Age-Related Medicine in Stavanger. The inclusion period lasted from February 28th to June 23rd 2022. Informed written consent was obtained from all participants.

Inclusion criteria: Either (i) or (ii). (i) Persons aged 40 years or older suspected by their GP to have possible dementia, based on history, clinical examination, and/or cognitive screening. These participants were recruited from the GP offices only. (ii) Assumed cognitively unimpaired

RESEARCH IN CONTEXT

- 1. Systematic Review:** Plasma tests for identifying Alzheimer's disease (AD) pathology may be useful in general practice. It is essential to understand certain pre-analytical conditions to facilitate the transition to clinical utility. We searched PubMed for articles on the effect of plasma storage temperature and duration on test results for amyloid- β ($A\beta$), tau, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). A recently published standardized operating procedure proposes plasma storage < 24 h at 2-8°C. Few other studies on the field exist. Preanalytical factors influencing p-tau231, one of the most novel phosphorylated tau isoforms, have not yet been tested.
- 2. Interpretation:** We found that plasma samples can be stored for up to 24 h at +4°C or +18°C and result in valid biomarker concentrations for p-tau181, p-tau231, $A\beta_{42}/A\beta_{40}$ ratio, GFAP, and NfL.
- 3. Future Directions:** Plasma biomarker analysis is suited for use in a primary care setting to aid the diagnosis of AD.

participants aged 65 years or above. These participants were recruited from the GP offices and from the Centre for Age-Related Medicine at Stavanger University Hospital.

Exclusion criteria applied to cognitively impaired participants: Either (i) or (ii). (i) Lack of capacity for consent as judged by the GP. (ii) Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.

A total of 13 participants were included, of whom 5 were female. Ten participants were cognitively unimpaired. Average age was 72, 5 years (standard deviation 6,7).

2.3 | Measures

Biomarker concentrations in plasma aliquots stored at -80°Celsius (°C) within 2 h of phlebotomy were compared with aliquots frozen 4 h, 6 h, 8 h, 10 h, and 24 h after phlebotomy, respectively stored at +4°C and at room temperature (mean +18.3°C) prior to ULTF.

2.4 | Procedure

2.4.1 | Sample handling

Blood samples were taken by phlebotomy between 8:15 am and 10 am and collected in tubes with K2-ethylenediaminetetraacetic acid (K2-EDTA). Three 6 mL tubes (Vacuette G456043) filled to maximum

volume were collected per participant. Fasting was not required. The time of phlebotomy was noted (hour and minute). Tubes were mixed by gently being inverted 5 to 10 times, thereafter centrifuged at 2200 \times g for 10 min at room temperature (RT). RT at this stage of the sample handling was defined as the temperature at the laboratories at the GP offices and at the research laboratory at Stavanger University Hospital and was not measured. Plasma was pipetted off using a low-density polyethylene transfer pipette (Sarstedt 86.1172.001), sparing out the buffy coat layer. Plasma from the same patient was pooled in a 15 mL polypropylene tube (Sarstedt 62.554.502). Tubes collected at the GP offices were stored in a refrigerator at +4°C and then transported in a cooling bag (Sarstedt 95.995) directly to the hospital laboratory arriving no later than 10:30 am. At the hospital laboratory, the plasma in the 15 mL polypropylene tubes was mixed by gently inverting the tube 10 times, then twelve 0.5 mL aliquots of the plasma sample were pipetted into polyethylene cryotubes (Sarstedt CryoPure tubes, 72.377) by using a low-density polyethylene transfer pipette. Half of the plasma aliquots were thereafter kept at +4°C and half were kept at RT. RT was automatically measured and adjusted, with the mean value being +18.3°C (minimum +16.1°C; maximum +19.5°C). One aliquot from each of these two groups was frozen at -80°C at defined time points: 10:30 to 11 am (depending on the time of phlebotomy), 12:30 pm, 2:30 pm, 4:30 pm, 6:30 pm, and 8 am, equivalent to storage duration approximately 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h after phlebotomy. The ultra-low-temperature-frozen cryotubes were stored at -80°C until samples from all participants had been collected, then sent from Stavanger to Gothenburg by temperature-regulated dry ice transport.

Plasma samples were analyzed at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. The laboratory was blinded to which aliquot had been frozen at which point of time and whether the aliquot had been stored at RT or at +4°C prior to freezing. Prior to analysis the plasma samples were thawed, vortexed at 2000 revolutions per minute for 30 s and centrifuged at 4000 \times g for 10 min at RT. Analyses were conducted no later than 30 min after plasma thawing. The 12 aliquots belonging to the same patient were always analyzed in succession in the same analytical run.

2.4.2 | Platform and assays

Plasma analysis was performed on the HD-X Analyzer (Quanterix). Plasma p-tau181 and p-tau231 concentrations were measured using in-house assays developed by the University of Gothenburg.^{8,10} Plasma $A\beta_{42}$, $A\beta_{40}$, GFAP, and NfL were measured using commercially available immunoassay from Quanterix (Neurology 4-Plex E).

2.5 | Statistics

Descriptive analyses were performed by estimating means and standard deviation (SD) for quantitative variables and percentages for categorical variables at 2 h (baseline), where sex and cognitive status were treated as dummy variables. Independent repeated

TABLE 1 Descriptive analysis for Time 2 h presented as mean \pm standard deviation (SD).

Variable	Room temp		Fridge +4C	
	Mean	\pm SD	Mean	\pm SD
Glial fibrillary acidic protein (GFAP)	118 ^a	103	123 ^a	101
Phosphorylated tau 231 (p-tau231)	17.3 ^a	3.4	16.9 ^a	3.5
Phosphorylated tau 181 (p-tau181)	16.1 ^a	9.4	16.2 ^a	10.2
Neurofilament light (NfL)	19.7 ^a	10.6	20.0 ^a	10.8
Amyloid- β 40 (A β 40)	92.7 ^a	20.5	92.8 ^a	25.6
Amyloid- β 42 (A β 42)	5.7 ^a	1.9	6.1 ^a	2.5
A β 42/40 ratio	0.06	0.02	0.07	0.02

^aBiomarker concentrations are given in picograms per milliliter (pg/mL).

measurements analysis of variance (ANOVA) were used for the longitudinal assessments for each variable, including two random effects: the variation within subjects as a variance component and the time-variation in each storage method as an unstructured variance component. p-tau181 and p-tau231 were logarithm-transformed to reach the normality assumption. One subject was excluded from the GFAP model since it was detected as an outlier. Also, a second subject was excluded for p-tau231. All models were adjusted for sex, age, and cognitive status. Where there was found no significant effect this adjustment was excluded to keep the models as simple as possible. Thus, the A β 40 model was adjusted by sex, the A β 42, A β 40/42, and p-tau181 models by sex and age, the GFAP and p-tau231 models by sex, and the NfL model by sex and cognitive status. The models were fitted by restricted maximum likelihood (REML), and the t-test for the hypothesis testing in the least squared means post-estimations used the Kenward-Roger method to estimate the degrees of freedom. Tukey's *p*-values adjustment was used to correct for multiple testing, and the hypotheses were rejected in each model on an alpha level of 0.05. PROC MIXED in SAS 9.4 was used for modeling and R version 4.2.1 for data manipulation and graphics.

2.6 | Ethics

The regional committee for medical and health research ethics approved the study on November 4th 2021 (REK Vest ID 206473). Informed written consent was obtained from all participants.

3 | RESULTS

Descriptive analyses at baseline are summarized in Table 1. Figure 1 shows median concentrations of plasma p-tau181, p-tau231, GFAP, NfL, A β 40, A β 42, and A β 42/A β 40 when plasma was stored at RT and when stored at +4°C for up to 24 h. Mean time between phlebotomy and ULT freezing of the first aliquot was 86 min (min. 40 min, max. 147 min, median 93 min).

We found no significant changes in concentrations of plasma p-tau181, p-tau231, and GFAP for neither the examined time nor temperature variables. For NfL, there was a significant difference in biomarker concentration comparing aliquots stored at +4°C versus RT after 8- and 10-h storage but not after 24 h. For A β 40 and A β 42, there were significant differences in biomarker concentrations between storage at +4°C and RT at 8 h, 10 h, and 24 h and between baseline and storage at RT for 24 h. For A β 40, there was also a significant difference in biomarker concentrations comparing storage at RT at baseline with storage after 10 h. For the A β 42 to A β 40 ratio, there was a significant difference comparing storage at +4°C and room temperature at 24 h but not compared with baseline. Significant findings are shown in Table 2. A table with all findings can be found in the [supplementary information](#).

4 | DISCUSSION

In a blinded, controlled study, we investigated if plasma sample storage duration and temperature before ultra-low temperature freezing causes changes in the concentration of six plasma biomarkers associated with Alzheimer's disease pathology. For p-tau181, p-tau231, and GFAP, we found no significant changes in biomarker concentrations during a storage time of 24 h, both when plasma was stored at room temperature and when stored at +4°C prior to ULTF, in other words, these storage factors do not seem to influence these plasma biomarker concentrations. To our knowledge, this study is the first to investigate these preanalytical qualities for plasma p-tau231. Even though calculation showed a significant difference in NfL biomarker concentration comparing storage between +4°C and RT after 8 and 10 h, we assume that this was due to normal variance as there was no significant difference in biomarker concentration after 24 h storage compared with baseline. For plasma A β 40 and A β 42 concentrations, the study found a clear temperature-dependent effect. Concentrations were stable for 24 h at +4°C but were reduced when kept at RT for 8 h or longer. When using the A β 42 to A β 40 ratio there was no significant change after 24 h storage at RT compared with baseline.

Our results are consistent with the findings of Verberk et al.¹⁸ In this study, plasma p-tau181, GFAP, and NfL concentrations were unaffected by post-centrifugation 24 h storage at either RT or 2-8°C, whereas the concentrations of plasma A β 40 and A β 42 showed a decline at RT. Plasma A β 40 and A β 42 values were stable at 2-8°C for 24 h, whereas in RT only for 4 h. In this study, no measurements between 4 and 24 h were conducted.

Using the A β 42/A β 40 ratio mitigated the observed decline during storage in RT in some but not all the immunoassays tested by Verberk et al.¹⁸ The assay used in our study was among those found to mitigate the decline in A β 40 and A β 42. Similarly, a study¹⁹ examined if there was a time- and temperature-dependent difference in plasma A β 40 and A β 42 values. This study found that A β 40 and A β 42 concentrations were stable up to 6 h but not 24 h when fresh EDTA plasma was stored at +4°C. The observed inter-immunoassay variability found by




FIGURE 1 Concentrations of plasma p-tau181, p-tau231, GFAP, NFL, A β 40, A β 42, and A β 42/A β 40 ratio (y-axis) when stored at +4°C and at room temperature for up to 24 h (x-axis). The horizontal line in each box represents the median, below and above are the second and third quartile. The lower whisker represents the first quartile, the upper whisker the fourth quartile. Outliers are represented as dots. Biomarker concentrations are given in picograms per milliliter (pg/ml). p-tau181, phosphorylated tau 181; p-tau231, phosphorylated tau 231; GFAP, glial fibrillary acidic protein; NFL, neurofilament light; A β 40, amyloid- β 40; A β 42, amyloid- β 42; A β 42/A β 40, amyloid- β 42 to amyloid- β 40 ratio; h, hour; C, Celcius.

Verberk et al.¹⁸ might explain why the results from Rozga et al.¹⁹ are somewhat different from ours.

We considered several preanalytical variables when planning this study. All our samples were collected in K2-ethylenediaminetetraacetic acid (K2-EDTA) tubes. Previous studies have shown that different blood collection tube types influence the measured amount of plasma biomarkers A β 42, A β 40, p-tau181, GFAP,

total tau, and NfL.^{18–20} K2-EDTA tubes have been suggested as a standard tube in a recently recommended standardized operating procedure.¹⁸ The effect of centrifugation temperature, aliquot volume and number of freeze-thaw-cycles has been tested for plasma p-tau181, GFAP, NfL, A β 40, and A β 42.^{18–21} No such studies for p-tau231 could be identified. We also considered if circadian rhythm might affect sample values. Rózga et al.¹⁹ found that plasma A β 40 and A β 42

TABLE 2 Findings of significant differences in estimated mean biomarker concentrations.

Variable	Comparison	Estimate	SE	p Value	Adj. p Value
Aβ40					
	Fridge +4C vs. Room Temp. at Time 8	7.0 ^a	1.6	0.001	0.000
	Fridge +4C vs. Room Temp. at Time 10	10.7 ^a	2.6	0.001	0.001
	Fridge +4C vs. Room Temp. at Time 24	17.8 ^a	2.2	<.001	<.001
	Room Temp. at Time 2 vs. at Time 10	-8.5 ^a	3.3	0.018	0.019
	Room Temp. at Time 2 vs. at Time 24	-16.6 ^a	3.1	<.001	<.001
Aβ42					
	Fridge +4C vs. Room Temp. at Time 8	0.5 ^a	0.2	0.027	0.022
	Fridge +4C vs. Room Temp. at Time 10	0.7 ^a	0.2	0.004	0.002
	Fridge +4C vs. Room Temp. at Time 24	1.5 ^a	0.2	<.001	<.001
	Room Temp. at Time 2 vs. at Time 24	-1.3 ^a	0.4	0.003	0.004
Aβ42/40					
	Fridge +4C vs. Room Temp. at Time 24	0.004	0.001	0.001	0.001
	Fridge +4C at Time 2 vs at Time 4	-0.004	0.002	0.020	0.021
NFL					
	Fridge +4C vs. Room Temp. at Time 8	0.8 ^a	0.3	0.018	0.008
	Fridge +4C vs. Room Temp. at Time 10	1.4 ^a	0.4	0.002	0.001

^aBiomarker concentrations are given in picograms per milliliter (pg/mL).

Abbreviations: Adj., adjusted.; A β 40, amyloid- β 40; A β 42, amyloid- β 42; A β 42/40, amyloid- β 42 to amyloid- β 40 ratio; C, Celcius; NFL, neurofilament light; SE, standard error; Temp., temperature; vs, versus.

showed a weak circadian rhythmicity. In our study, all blood samples were drawn in the morning, and we therefore do not expect that our results are influenced by circadian rhythmicity variability. The effect of tube material, tube size and the presence of gel separators has not been found to influence the quantification of plasma A β 40 and A β 42.¹⁹ RT in our study was between +16.1 to 19.5°C. Higher storage temperatures might have a different effect on plasma biomarker levels than found in this study.

We consider it a strength that more than half of the blood samples were drawn in general practitioner's offices following a standardized procedure. Overall, there were no difficulties related to this setting. Time of phlebotomy at the GP offices had to be adjusted to real-life clinical situations, for example, when participants had their visit scheduled. Time of phlebotomy varied from 8:13 am to 9:59 am. In two of the 13 cases, it took 143 and 137 min, respectively, to freeze the first aliquot, whereas the protocol planned for a maximum time of 120 min. We have no reason to believe that this affected the overall results. We did not include centrifugation-postponed EDTA-blood samples in our project. Blood samples stored before centrifugation might have worse biomarker stability than plasma stored after centrifugation, although Verberk et al.¹⁸ did not find such differences for p-tau181, GFAP, and NfL, and for A β 42/A β 40 ratio only for some immunoassays. From a primary care perspective, it could be labor- and time-saving to send blood samples uncentrifuged and postpone centrifugation and plasma-pipetting to a centralized laboratory having access to an ultra-low temperature freezer. On the other hand,

it could be overall time-saving if the centralized laboratories receive plasma samples that can be frozen immediately without further handling.

A strength in our study is that we have included two phosphorylated tau isoforms, currently seen as some of the most promising plasma biomarkers for diagnosing AD pathology, as well as the A β 42/A β 40 ratio, the astrogliosis biomarker GFAP and NFL, a marker for axonal neurodegeneration. This allows for comparing their sensitivities to variation in pre-analytical factors such as sample storage time and temperature. This information is important in the design of future clinical trials that consider decentralized sampling of plasma samples for AD-related biomarkers.

We did not assess the participants' cognitive status with tests before inclusion, which might be considered a limitation of our study. We included participants whose primary care doctor suspected possible cognitive impairment due to dementia and elderly participants without known cognitive impairment. However, as our aim was not to assess the diagnostic ability of the biomarkers but the effect of sample storage time and temperature on assay results, this is considered negligible. There is no reason to believe that cognitive status would influence biomarker stability. Other studies on preanalytical qualities of plasma biomarkers have included healthy volunteers¹⁹ or adults who presented for a diagnostic blood draw for any disease.¹⁸ The low number of participants in our study might be seen as a limitation. This is outweighed by the high number of aliquots per participant, creating a total of 156 measurements per biomarker.

4.1 | Implications for clinical use

In conclusion, we found that K2-EDTA plasma samples can be stored for 24 h at +4°C or at a room temperature of +18°C before ULTF and still result in valid assay results for a panel of phosphorylated tau isoforms p-tau181 and p-tau231, A β 42/A β 40 ratio, GFAP, and NfL. Therefore, plasma samples for these biomarkers seem suitable for use in a primary care setting where sample storage and transportation to a facility with ultra-low temperature freezing can be achieved within this frame.

AUTHOR CONTRIBUTION

Anita L. Sunde contributed to the development of the concept and design of the study, the practical work of including participants, collection and freezing of the samples, analysis and interpretation of the results as well as preparation of the manuscript. Ingvild V. Alsnes, Dag Aarsland, Kaj Blennow, Henrik Zetterberg, and Svein Kjosavik had an important role in the establishment of the research group, the application for funds and the overall project plan of which this study is a part of. Nicholas J. Ashton, Giovanni De Santis, Kaj Blennow, and Henrik Zetterberg contributed regarding the plasma biomarker analysis. Diego A. Tovar-Rios was mainly involved in the statistical assessment of the data. In addition, all authors contributed to revising the manuscript.

ACKNOWLEDGMENTS

The authors thank all participants for donating their blood for research purposes. The authors thank the participating GP offices for their time and willingness to help. The authors thank the research laboratory at Stavanger University Hospital for their help with sample handling.

This work was supported by the Western Norway Regional Health Authority (grant number F-12583, 2021). H. Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003).

CONFLICT OF INTEREST STATEMENT

A.L. Sunde, I.V. Alsnes, N.J. Ashton, D.A. Tovar-Rios, G. De Santis, and S.R. Kjosavik report no conflict of interest. K. Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothema,

Roche Diagnostics, and Siemens Healthineers; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). D. Aarsland has received a research grant and honoraria from Roche Diagnostics (outside submitted work). Author disclosures are available in the [supporting information](#).

ORCID

Anita L. Sunde  <https://orcid.org/0000-0003-0854-470X>

REFERENCES

- Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. *The Lancet*. 2021;397:1577-1590. doi:10.1016/s0140-6736(20)32205-4
- Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y-T, Prina M. World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. 2015.
- Chong JR, Ashton NJ, Karikari TK, et al. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. *J Neurol Neurosurg Psychiatry*. 2021;92:1231-1241. doi:10.1136/jnnp-2021-327370
- Chen L, Niu X, Wang Y, et al. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. *Front Aging Neurosci*. 2022;14:942629. doi:10.3389/fnagi.2022.942629
- Qu Y, Ma Y-H, Huang Y-Y, et al. Blood biomarkers for the diagnosis of amnesic mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2021;128:479-486. doi:10.1016/j.neubiorev.2021.07.007
- Pichet Binette A, Palmqvist S, Bali D, et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. *Alzheimers Res Ther*. 2022;14:46. doi:10.1186/s13195-022-00990-0
- Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. *Nat Med*. 2021;27:1034-1042. doi:10.1038/s41591-021-01348-z
- Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol*. 2020;19:422-433. doi:10.1016/S1474-4422(20)30071-5
- Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med*. 2020;26:379-386. doi:10.1038/s41591-020-0755-1
- Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathol*. 2021;141:709-724. doi:10.1007/s00401-021-02275-6

11. Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. *Brain*. 2021. doi:[10.1093/brain/awab223](https://doi.org/10.1093/brain/awab223)
12. Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β -amyloid status. *JAMA Neurol*. 2019;76:1060-1069. doi:[10.1001/jamaneurol.2019.1632](https://doi.org/10.1001/jamaneurol.2019.1632)
13. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun*. 2021;12:3400. doi:[10.1038/s41467-021-23620-z](https://doi.org/10.1038/s41467-021-23620-z)
14. Thijsen EH, Verberk IMW, Kindermans J, et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. *Alzheimers Dement*. 2022;14:e12285. doi:[10.1002/dad2.12285](https://doi.org/10.1002/dad2.12285)
15. Michelet M, Lund A, Strand BH, Engedal K, Selbaek G, Bergh S. Characteristics of patients assessed for cognitive decline in primary healthcare, compared to patients assessed in specialist healthcare. *Scand J Prim Health Care*. 2020;38:107-116. doi:[10.1080/02813432.2020.1753334](https://doi.org/10.1080/02813432.2020.1753334)
16. de Levante Raphael D. The knowledge and attitudes of primary care and the barriers to early detection and diagnosis of Alzheimer's disease. *Medicina*. 2022;58:906. doi:[10.3390/medicina58070906](https://doi.org/10.3390/medicina58070906)
17. Mansfield E, Noble N, Sanson-Fisher R, Mazza D, Bryant J. Primary care physicians' perceived barriers to optimal dementia care: a systematic review. *Gerontologist*. 2019;59:e697-708. doi:[10.1093/geront/gny067](https://doi.org/10.1093/geront/gny067)
18. Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. *Alzheimers Dement*. 2021. doi:[10.1002/alz.12510](https://doi.org/10.1002/alz.12510)
19. Rózga M, Bittner T, Batrla R, Karl J. Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers. *Alzheimers Dement*. 2019;11:291-300. doi:[10.1016/j.dadm.2019.02.002](https://doi.org/10.1016/j.dadm.2019.02.002)
20. Ashton NJ, Suárez-Calvet M, Karikari TK, et al. Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. *Assessment & Disease Monitoring*. 2021;13:e12168. doi:[10.1002/dad2.12168](https://doi.org/10.1002/dad2.12168) Alzheimer's & Dementia: Diagnosis
21. Keshavan A, Heslegrave A, Zetterberg H, Schott JM. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. *Assessment & Disease Monitoring*. 2018;10:448-451. doi:[10.1016/j.dadm.2018.06.001](https://doi.org/10.1016/j.dadm.2018.06.001). Alzheimer's & Dementia: Diagnosis.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Sunde AL, Alsnes IV, Aarsland D, et al. Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology. *Alzheimer's Dement*. 2023;15:e12439. <https://doi.org/10.1002/dad2.12439>